As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a recent study focused on patient-reported outcomes in resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib.
Independent expert commentary is provided by Associate Professor Matteo Carlino, a Medical Oncologist at Westmead and Blacktown Hospitals, and Clinical Associate Professor at The University of Sydney.
Please login below to download this issue (PDF)